https://transhumanist.ru/index.php?action=history&feed=atom&title=ADORA2B 2026-04-05T14:07:31Z История изменений этой страницы в вики MediaWiki 1.43.6 https://transhumanist.ru/index.php?title=ADORA2B&diff=5828&oldid=prev 2021-05-12T14:54:47Z

<p>Новая страница: «Adenosine receptor A2b ==Publications== {{medline-entry |title=Adenosine A2B receptor: A pathogenic factor and a therapeutic target for sensorineural hearing lo...»</p> <p><b>Новая страница</b></p><div>Adenosine receptor A2b<br /> <br /> ==Publications==<br /> <br /> {{medline-entry<br /> |title=Adenosine A2B receptor: A pathogenic factor and a therapeutic target for sensorineural hearing loss.<br /> |pubmed-url=https://pubmed.ncbi.nlm.nih.gov/33131093<br /> |abstract=Over 466 million people worldwide are diagnosed with hearing loss (HL). About 90% of HL cases are sensorineural HL (SNHL) with treatments limited to hearing aids and cochlear implants with no FDA-approved drugs. Intriguingly, [[ADA]]-deficient patients have been reported to have bilateral SNHL, however, its underlying cellular and molecular basis remain unknown. We report that Ada mice, phenocopying [[ADA]]-deficient humans, displayed SNHL. Ada mice cochlea with elevated adenosine caused substantial nerve fiber demyelination and mild hair cell loss. [[ADA]] enzyme therapy in these mice normalized cochlear adenosine levels, attenuated SNHL, and prevented demyelination. Additionally, [[ADA]] enzyme therapy rescued SNHL by restoring nerve fiber structure in Ada mice post two-week drug withdrawal. Moreover, elevated cochlear adenosine in untreated mice was associated with enhanced Adora2b gene expression. Preclinically, [[ADORA2B]]-specific antagonist treatment in Ada mice significantly improved HL, nerve fiber density, and myelin compaction. We also provided genetic evidence that [[ADORA2B]] is detrimental for age-related SNHL by impairing cochlear myelination in WT aged mice. Overall, understanding purinergic molecular signaling in SNHL in Ada mice allows us to further discover that [[ADORA2B]] is also a pathogenic factor underlying aged-related SNHL by impairing cochlear myelination and lowering cochlear adenosine levels or blocking [[ADORA2B]] signaling are effective therapies for SNHL.<br /> <br /> |keywords=* ADA-deficiency<br /> * adenosine deaminase deficiency<br /> * aging<br /> * myelin protein zero<br /> * myelination<br /> |full-text-url=https://sci-hub.do/10.1096/fj.202000939R<br /> }}</div>

OdysseusBot